Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET
Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCMtrial in patients with obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The team will be joined by CIRRUS-HCM investigator, Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Associate Professor of Medicine, University of Pennsylvania, who will share her perspective of EDG-7500 and HCM. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page.
领先的肌肉病生物制药公司Edgewise Therapeutics, Inc.（纳斯达克股票代码：EWTX）今天宣布，管理团队成员将于美国东部时间2024年9月19日星期四上午8点30分举行网络直播，讨论针对健康受试者的1期试验和Cirrus-HCM试验的单剂量组的 EDG-7500 主要数据。Cirrus-HCM 研究员、宾夕法尼亚大学遗传性心脏病中心医学主任、医学副教授 Anjali t. Owenswand.D. 将加入该团队，她将分享她对 EDG-7500 和 HCm 的看法。还将提供随附的幻灯片演示。要注册网络直播和重播，请访问 Edgewise 活动页面。
